|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
CLARITHROMYCIN INCREASES PLASMA CONCENTRATION BY 30% AND MEAN HALF LIFE FROM 1.2 TO 1.6 HRS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
DILTIAZEM INHIBIT CYP-450 ENZYME THUS REDUCING THE CLEARANCE OF THE DRUG, HENCE DOSE OF THE DRUG SHOULD BE REDUCED
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
SELECTIVE SEROTONIN INHIBITORS MAY INHIBIT ITS ELIMINATION LEADING TO INCREASED BLOOD LEVELS
|
VERAPAMIL INHIBITS METABOLISM OF THE DRUG
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MICONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
EFAVIRENZ CAN INHIBIT ITS METABOLISM CAUSING RAISED PLASMA LEVELS
|
OXICONAZOLE CAN INHIBIT ITS METABOLISM THERE BY INCREASING SERUM LEVELS
|
QUININE INHIBITS ITS METABOLISM LEADING TO INCREASED PLASMA LEVELS
|
FLUOXETINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
FLUVOXAMINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|